Inventor · disambiguated record
James E. Bradner
Also filed as: BRADNER JAMES · BRADNER JAMES E · BRADNER JAMES ELLIOT
33 granted patents·21 pending applications·259 citations·filing 2006–2023
97Inventor score
Files withDANA FARBER CANCER INST INC19HARVARD COLLEGE9BRADNER JAMES ELLIOT3MAZITSCHEK RALPH3VAN DUZER JOHN H3
Top patents by PatentIndex Score
54 records- 0197US10849980B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2019·Granted Dec 1, 2020·16 cites·45 claims
- 0296US11583586B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2020·Granted Feb 21, 2023·3 cites·21 claims
- 0395US8148526B1Reverse amide compounds as protein deacetylase inhibitors and methods of use thereofVAN DUZER JOHN H·Filed 2011·Granted Apr 3, 2012·38 cites·4 claims
- 0494US8609678B2Reverse amide compounds as protein deacetylase inhibitors and methods of use thereofVAN DUZER JOHN H·Filed 2012·Granted Dec 17, 2013·30 cites·9 claims
- 0594US8394810B2Reverse amide compounds as protein deacetylase inhibitors and methods of use thereofVAN DUZER JOHN H·Filed 2011·Granted Mar 12, 2013·32 cites·4 claims
- 0692US8383855B2Histone deacetylase inhibitorsHARVARD COLLEGE·Filed 2007·Granted Feb 26, 2013·14 cites·35 claims
- 0791US11311609B2Regulating chimeric antigen receptorsDANA FARBER CANCER INST INC·Filed 2018·Granted Apr 26, 2022·6 cites·29 claims
- 0890US11059801B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2020·Granted Jul 13, 2021·2 cites·22 claims
- 0990US8999289B2Treatment of protein degradation disordersANDERSON KENNETH C·Filed 2006·Granted Apr 7, 2015·16 cites·32 claims
- 1090US8754237B2Bifunctional histone deacetylase inhibitorsBRADNER JAMES ELLIOT·Filed 2012·Granted Jun 17, 2014·18 cites·13 claims
- 1187US9572854B2Treatment of protein degradation disordersHARVARD COLLEGE·Filed 2015·Granted Feb 21, 2017·6 cites·20 claims
- 1287US8440716B2Deacetylase inhibitors and uses thereofTANG WEIPING·Filed 2009·Granted May 14, 2013·18 cites·19 claims
- 1386US11046954B2Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responsesDANA FARBER CANCER INST INC·Filed 2018·Granted Jun 29, 2021·2 cites·17 claims
- 1486US10899768B2Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Jan 26, 2021·3 cites·19 claims
- 1586US8716344B2Class- and isoform-specific HDAC inhibitors and uses thereofMAZITSCHEK RALPH·Filed 2010·Granted May 6, 2014·8 cites·21 claims
- 1686US8304451B2Histone deacetylase and tubulin deacetylase inhibitorsMAZITSCHEK RALPH·Filed 2007·Granted Nov 6, 2012·11 cites·31 claims
- 1785US11285218B2Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Mar 29, 2022·5 cites·4 claims
- 1884US8222423B2Bifunctional histone deacetylase inhibitorsBRADNER JAMES ELLIOT·Filed 2007·Granted Jul 17, 2012·17 cites·13 claims
- 1983US10172905B1Treatment of protein degradation disordersHARVARD COLLEGE·Filed 2017·Granted Jan 8, 2019·3 cites·20 claims
- 2082US9199923B2Histone deacetylase inhibitorsHARVARD COLLEGE·Filed 2014·Granted Dec 1, 2015·3 cites·22 claims
- 2177US9540317B2Class- and isoform-specific HDAC inhibitors and uses thereofHARVARD COLLEGE·Filed 2014·Granted Jan 10, 2017·2 cites·39 claims
- 2275US9724321B2Histone deacetylase inhibitorsHARVARD COLLEGE·Filed 2015·Granted Aug 8, 2017·1 cites·19 claims
- 2374US9434686B2Deacetylase inhibitors and uses thereofHARVARD COLLEGE·Filed 2013·Granted Sep 6, 2016·2 cites·24 claims
- 2474US2022135967A1Tunable endogenous protein degradationDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 2573US9567301B2Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitorsWHITEHEAD INST BIOMEDICAL RES·Filed 2013·Granted Feb 14, 2017·1 cites·10 claims
- 2671US2018085465A1Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2017·Application pending·0 cites
- 2771US2021301286A1Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responsesDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2870US11617750B2Reverse amide compounds as protein deacetylase inhibitors and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2019·Granted Apr 4, 2023·0 cites·13 claims
- 2970US10702504B2Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Jul 7, 2020·1 cites·16 claims
- 3070US10071129B2Method for identifying bromodomain inhibitorsYOUNG RICHARD A·Filed 2012·Granted Sep 11, 2018·1 cites·6 claims
- 3168US11293023B2Tunable endogenous protein degradationDANA FARBER CANCER INST INC·Filed 2018·Granted Apr 5, 2022·0 cites·13 claims
- 3266US2024140999A1Stabilized peptide-mediated targeted protein degradationDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 3364US10172821B2Histone deacetylase inhibitorsHARVARD COLLEGE·Filed 2017·Granted Jan 8, 2019·0 cites·12 claims
- 3464US2015045380A1Reverse amide compounds as protein deacetylase inhibitors and methods of use thereofACETYLON PHARMACEUTICALS·Filed 2014·Application pending·0 cites
- 3562US2014142117A1Reverse amide compounds as protein deacetylase inhibitors and methods of use thereofACETYLON PHARMACEUTICALS·Filed 2013·Application pending·0 cites
- 3660US2019134141A1Methods of downregulating translocated oncogene expression using bromodomain inhibitorsWHITEHEAD INST BIOMEDICAL RES·Filed 2018·Application pending·0 cites
- 3760US2014213620A1Histone deacetylase inhibitorsBRADNER JAMES ELLIOT·Filed 2013·Application pending·0 cites
- 3860US2016375021A1Reverse amide compounds as protein deacetylase inhibitors and methods of use thereofACETYLON PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3958US10059657B2Class-and isoform-specific HDAC inhibitors and uses thereofHARVARD COLLEGE·Filed 2017·Granted Aug 28, 2018·0 cites·16 claims
- 4058US2020121721A1Methods for genetic modification of hematopoietic cellsBRIGHAM & WOMENS HOSPITAL INC·Filed 2019·Application pending·0 cites
- 4155US10925868B2Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Feb 23, 2021·0 cites·19 claims
- 4255US2024309084A1Degradation of extracellular targetsNOVARTIS AG·Filed 2022·Application pending·0 cites
- 4350US2020354413A1Stabilized peptide-mediated targeted protein degradationDANA FARBER CANCER INST INC·Filed 2018·Application pending·0 cites
- 4449US2009221433A1Small molecule printingBARNES DAVID W·Filed 2007·Application pending·0 cites
- 4549US2013261023A1Small molecule printingBARNES DAVID W·Filed 2012·Application pending·0 cites
- 4648US12023385B2Tunable endogenous protein degradation with heterobifunctional compoundsDANA FARBER CANCER INST INC·Filed 2018·Granted Jul 2, 2024·0 cites·24 claims
- 4747US10087149B2Selective histone deacetylase 8 inhibitorsUNIV BOSTON·Filed 2014·Granted Oct 2, 2018·0 cites·18 claims
- 4845US2017173083A1Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cellsBRIGHAM & WOMENS HOSPITAL INC·Filed 2015·Application pending·0 cites
- 4942US2015197497A1Selective inhibitors of histone deacetylase isoform 6 and methods thereofABEYWICKRAMA CHANDIMA·Filed 2012·Application pending·0 cites
- 5042US2015167062A1Genome-wide Method of Assessing Interactions Between Chemical Entities And Their Target MoleculesWHITEHEAD BIOMEDICAL INST·Filed 2013·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →